FARGLITAZAR

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H30N2O5
Molecular Weight	546.6124
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CCOC2=CC=C(C[C@H](NC3=CC=CC=C3C(=O)C4=CC=CC=C4)C(O)=O)C=C2)N=C(O1)C5=CC=CC=C5

InChI

InChIKey=ZZCHHVUQYRMYLW-HKBQPEDESA-N

InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C34H30N2O5
Molecular Weight	546.6124
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800008802 | https://www.ncbi.nlm.nih.gov/pubmed/26633022 | https://www.ncbi.nlm.nih.gov/pubmed/20444603

Farglitazar is a non-thiazolidinedione insulin sensitizer and agonist of peroxisome proliferator-activated receptor-gamma. GlaxoSmithKline was developing farglitazar for the treatment of liver fibrosis and Type 2 diabetes mellitus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor gamma 118 Target ID: P37231\|\|\|Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26633022 \| https://www.ncbi.nlm.nih.gov/pubmed/20444603	Agonist 2752

PubMed

Title	Date	PubMed
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.	2011-12-22	22070604
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.	2005-09-16	16168052
GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.	2005-02	15475592
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.	2005-01	15452359
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.	2004-12-15	15556564
Binding analyses between Human PPARgamma-LBD and ligands.	2004-01	14717706
Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays.	2003-10-01	13129568
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.	2000-03	10882139
The PPARs: from orphan receptors to drug discovery.	2000-02-24	10691680
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.	1998-12-03	9836620

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:03:31 GMT 2025` Edited by `admin` on `Wed Apr 02 07:03:31 GMT 2025`
Record UNII	3433GY7132
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FARGLITAZAR

Official Name

English

G1-262570

Preferred Name

English

Farglitazar [WHO-DD]

Common Name

English

GI-262570X

Code

English

N-(O-BENZOYLPHENYL)-O-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHYL)-L-TYROSINE

Common Name

English

farglitazar [INN]

Common Name

English

GI-262570

Code

English

L-TYROSINE, N-(2-BENZOYLPHENYL)-O-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHYL)-

Systematic Name

English

GI262570X

Code

English

FARGLITAZAR [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98233